Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosi...(m cell expert from Aristotle University....)

Date:11/3/2009

m cell expert from Aristotle University. Initially, the medical team in Greece gave Mr. Kanelos intravenous therapy of his own adipose-derived stem cells. When a slight improvement was seen in the patient's pulmonary function tests Professor Bouros suggested administering the stem cells directly into the lungs, a previously untried method, but one which might give even better results. After receiving institutional ethics approval, the ten minute direct administration procedure was later successfully carried out by bronchoscopy with the patient under local anesthesia.

Mr Kanelos is now back home with his family in Athens awaiting results of the stem cell therapy due in a few months. Upon interview, Mr. Kanelos said "I hope it works for me, as it will give hope to the thousands of terminal sufferers around the world who cannot get a lung donor". There are five million people worldwide that are affected by idiopathic pulmonary fibrosis. There are over 500,000 patients in the USA alone, where lung transplants are more easily available, and of these, more than 40,000 die from the disease annually.

Said Brian Dardzinski, Adistem Business Manager, "This imaginative approach by Professor Bouros and his team represents another important step forward in adipose-derived stem cell therapy. For pulmonary fibrosis patients around the world it offers the possibility of a life saving procedure. For medicine, it offers a new and possibly effective avenue of treatment for a host of life threatening conditions."

For further information and business queries, please visit '/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Researcher honored for experimental work in nanotechnology
2. Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project
3. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
4. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
5. LX211 highlighted as potential disease modifying therapy for noninfectious uveitis
6. Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes
7. Lubris, Biomodels Report on Potential New Therapy for Osteoarthritis
8. SourceMedical's Therapy Software Partners with FOTO, the Leading Provider of Patient Outcome Surveys
9. Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
10. Topical erectile dysfunction therapy shows promise
11. STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial